EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 18 2024
0mins
Source: Benzinga
- GLP-1 Market Leaders Face Selloff: Eli Lilly and Novo Nordisk experienced a significant drop in stock prices due to competition from new weight-loss drugs developed by other pharmaceutical companies.
- Competition and Future Outlook: The entry of Pfizer and Roche into the obesity-fighting drug market poses a threat to the dominance of Novo and Lilly, with potential for up to five credible players in the GLP-1 market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 329.130
Low
280.00
Averages
363.10
High
425.00
Current: 329.130
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amgen Secures EU Approval for Antitumor Drug Imdelltra
- Drug Approval: Amgen's antitumor agent Imdelltra (tarlatamab) has received marketing authorization from the European Commission, providing a late-line treatment option for specific small cell lung cancer patients, marking a significant expansion in the company's oncology portfolio.
- Clinical Data Support: The approval is backed by data from the DeLLphi-304 Phase 3 trial, which demonstrated that Imdelltra reduced mortality risk by 40% compared to standard chemotherapy, significantly improving patient survival rates and enhancing its competitive position in the market.
- Market Timing: The EU approval for Imdelltra comes shortly after its full FDA approval in November, indicating Amgen's rapid global market positioning to meet the increasing demand for small cell lung cancer treatments.
- Strategic Implications: This approval not only opens a new revenue stream for Amgen but also reinforces its leadership in the biopharmaceutical sector, expected to drive future growth and innovation for the company.
See More
Amgen to Present at Jefferies Global Healthcare Conference
- Conference Schedule: Amgen will participate in the Jefferies Global Healthcare Conference on June 4, 2026, at 9:55 a.m. ET, showcasing its latest advancements in the biopharmaceutical sector, which is expected to attract significant attention from investors and media.
- Executive Team Participation: The executive team from Amgen, including CFO Peter Griffith, SVP of Global Development Narimon Honarpour, and SVP of Global Marketing and Access Kave Niksefat, will collectively present at the conference, highlighting the company's strategic direction and business developments.
- Webcast Availability: The conference will feature a live webcast accessible to media, investors, and the public, with Amgen providing relevant links on its website to ensure transparency and accessibility of information.
- Company Background: Founded over 45 years ago, Amgen is dedicated to developing innovative medicines to combat major global diseases, and as a component of the Dow Jones Industrial Average and Nasdaq-100 Index, it underscores its leadership and ongoing innovation in the biotechnology industry.
See More
Global Firms Innovate AI Applications in India
- AI in Healthcare: Apollo Hospitals in India has partnered with Microsoft to deploy an AI clinical assistant that helps doctors quickly gather patient data and generate insights, effectively giving back 20% of their time, which indirectly enhances patient care efficiency.
- Retail Sector Innovation: Catalyst Brands is piloting computer-generated imagery technology at its Bengaluru center to reduce the need for global inventory movement for product shoots, which not only improves efficiency but also lowers operational costs.
- Marketing Automation: Kimberly-Clark is leveraging AI to accelerate marketing processes by developing internal tools that identify and evaluate social media influencers, thereby expanding product promotion reach and enhancing brand impact.
- AI Integration in Pharmaceuticals: Novo Nordisk is deploying AI across critical drug launch processes, including drafting regulatory documents and analyzing safety data, which is expected to save millions of dollars and improve overall operational efficiency.
See More
Analyst Blog Highlights Stocks: RTX, Wells Fargo, Amgen
- RTX Strong Performance: RTX's shares have surged 33.7% over the past year, significantly outperforming the Aerospace - Defense industry’s 3.5% growth, indicating robust demand for defense product orders and commercial aerospace, despite uncertainties from U.S. import tariffs.
- Wells Fargo Revenue Challenges: While Wells Fargo's shares have gained 6.4% over the past year, its net interest income recovery remains slow, with anticipated Fed rate cuts in 2026 pressuring revenue growth, highlighting competitive pressures in the financial market.
- Amgen Sales Growth: Amgen's shares have increased by 24.8% over the past year, driven by strong sales of key medicines, although facing challenges from biosimilar competition and price declines, showcasing its robust performance in the biomedical sector.
- Daily Journal Successful Transformation: Daily Journal's shares have risen 12.2% over the past year, with a market capitalization of $652.05 million, as its software-driven business model increasingly replaces traditional publishing, reflecting growth potential in government software solutions.
See More
Surge in Options Volume for LULU and AMGN
- LULU Options Volume: As of now, LULU's options volume has reached 14,930 contracts, equivalent to approximately 1.5 million shares, representing 47% of its average daily trading volume of 3.2 million shares over the past month, indicating a significant increase in market interest.
- High-Frequency Contracts: Within LULU, the $150 strike call option has shown particularly high activity, with 2,116 contracts traded today, representing about 211,600 shares, reflecting strong investor expectations for future price increases.
- AMGN Options Activity: Concurrently, AMGN's options volume stands at 12,758 contracts, approximately 1.3 million shares, accounting for 45.7% of its average daily trading volume of 2.8 million shares over the past month, showcasing the stock's market activity.
- Key Contract Analysis: For AMGN, the $440 strike call option has been notably active, with 8,267 contracts traded today, representing around 826,700 shares, indicating optimistic sentiment among investors regarding the stock's future performance.
See More
Market Timing and Dividend Growth Strategy
- Market Timing: By implementing a dollar-cost averaging (DCA) strategy, investors can reduce risk during market fluctuations, ensuring fewer shares are purchased when prices are high and more when prices are low, thereby optimizing portfolio returns.
- Dividend Reinvestment Plans: Utilizing Dividend Reinvestment Plans (DRIP), investors can automatically reinvest dividends, enhancing long-term returns, akin to a workout routine that continuously builds investment value and income streams.
- Dividend Magnet Effect: Companies like Visa and Amgen exhibit a 'Dividend Magnet' effect, where their dividend growth trends support stock prices during market downturns; Visa has increased its dividend by 378% over the past decade and repurchased 19% of its shares, showcasing strong market performance.
- Investment Opportunities: Now is an opportune time to invest in Visa and Amgen, especially during price dips; leveraging the DCA strategy along with extra cash purchases can further enhance investment returns, ensuring stable gains amid market volatility.
See More
Amgen Secures EU Approval for Antitumor Drug Imdelltra
- Drug Approval: Amgen's antitumor agent Imdelltra (tarlatamab) has received marketing authorization from the European Commission, providing a late-line treatment option for specific small cell lung cancer patients, marking a significant expansion in the company's oncology portfolio.
- Clinical Data Support: The approval is backed by data from the DeLLphi-304 Phase 3 trial, which demonstrated that Imdelltra reduced mortality risk by 40% compared to standard chemotherapy, significantly improving patient survival rates and enhancing its competitive position in the market.
- Market Timing: The EU approval for Imdelltra comes shortly after its full FDA approval in November, indicating Amgen's rapid global market positioning to meet the increasing demand for small cell lung cancer treatments.
- Strategic Implications: This approval not only opens a new revenue stream for Amgen but also reinforces its leadership in the biopharmaceutical sector, expected to drive future growth and innovation for the company.
See More
Amgen to Present at Jefferies Global Healthcare Conference
- Conference Schedule: Amgen will participate in the Jefferies Global Healthcare Conference on June 4, 2026, at 9:55 a.m. ET, showcasing its latest advancements in the biopharmaceutical sector, which is expected to attract significant attention from investors and media.
- Executive Team Participation: The executive team from Amgen, including CFO Peter Griffith, SVP of Global Development Narimon Honarpour, and SVP of Global Marketing and Access Kave Niksefat, will collectively present at the conference, highlighting the company's strategic direction and business developments.
- Webcast Availability: The conference will feature a live webcast accessible to media, investors, and the public, with Amgen providing relevant links on its website to ensure transparency and accessibility of information.
- Company Background: Founded over 45 years ago, Amgen is dedicated to developing innovative medicines to combat major global diseases, and as a component of the Dow Jones Industrial Average and Nasdaq-100 Index, it underscores its leadership and ongoing innovation in the biotechnology industry.
See More
Global Firms Innovate AI Applications in India
- AI in Healthcare: Apollo Hospitals in India has partnered with Microsoft to deploy an AI clinical assistant that helps doctors quickly gather patient data and generate insights, effectively giving back 20% of their time, which indirectly enhances patient care efficiency.
- Retail Sector Innovation: Catalyst Brands is piloting computer-generated imagery technology at its Bengaluru center to reduce the need for global inventory movement for product shoots, which not only improves efficiency but also lowers operational costs.
- Marketing Automation: Kimberly-Clark is leveraging AI to accelerate marketing processes by developing internal tools that identify and evaluate social media influencers, thereby expanding product promotion reach and enhancing brand impact.
- AI Integration in Pharmaceuticals: Novo Nordisk is deploying AI across critical drug launch processes, including drafting regulatory documents and analyzing safety data, which is expected to save millions of dollars and improve overall operational efficiency.
See More
Analyst Blog Highlights Stocks: RTX, Wells Fargo, Amgen
- RTX Strong Performance: RTX's shares have surged 33.7% over the past year, significantly outperforming the Aerospace - Defense industry’s 3.5% growth, indicating robust demand for defense product orders and commercial aerospace, despite uncertainties from U.S. import tariffs.
- Wells Fargo Revenue Challenges: While Wells Fargo's shares have gained 6.4% over the past year, its net interest income recovery remains slow, with anticipated Fed rate cuts in 2026 pressuring revenue growth, highlighting competitive pressures in the financial market.
- Amgen Sales Growth: Amgen's shares have increased by 24.8% over the past year, driven by strong sales of key medicines, although facing challenges from biosimilar competition and price declines, showcasing its robust performance in the biomedical sector.
- Daily Journal Successful Transformation: Daily Journal's shares have risen 12.2% over the past year, with a market capitalization of $652.05 million, as its software-driven business model increasingly replaces traditional publishing, reflecting growth potential in government software solutions.
See More
Surge in Options Volume for LULU and AMGN
- LULU Options Volume: As of now, LULU's options volume has reached 14,930 contracts, equivalent to approximately 1.5 million shares, representing 47% of its average daily trading volume of 3.2 million shares over the past month, indicating a significant increase in market interest.
- High-Frequency Contracts: Within LULU, the $150 strike call option has shown particularly high activity, with 2,116 contracts traded today, representing about 211,600 shares, reflecting strong investor expectations for future price increases.
- AMGN Options Activity: Concurrently, AMGN's options volume stands at 12,758 contracts, approximately 1.3 million shares, accounting for 45.7% of its average daily trading volume of 2.8 million shares over the past month, showcasing the stock's market activity.
- Key Contract Analysis: For AMGN, the $440 strike call option has been notably active, with 8,267 contracts traded today, representing around 826,700 shares, indicating optimistic sentiment among investors regarding the stock's future performance.
See More
Market Timing and Dividend Growth Strategy
- Market Timing: By implementing a dollar-cost averaging (DCA) strategy, investors can reduce risk during market fluctuations, ensuring fewer shares are purchased when prices are high and more when prices are low, thereby optimizing portfolio returns.
- Dividend Reinvestment Plans: Utilizing Dividend Reinvestment Plans (DRIP), investors can automatically reinvest dividends, enhancing long-term returns, akin to a workout routine that continuously builds investment value and income streams.
- Dividend Magnet Effect: Companies like Visa and Amgen exhibit a 'Dividend Magnet' effect, where their dividend growth trends support stock prices during market downturns; Visa has increased its dividend by 378% over the past decade and repurchased 19% of its shares, showcasing strong market performance.
- Investment Opportunities: Now is an opportune time to invest in Visa and Amgen, especially during price dips; leveraging the DCA strategy along with extra cash purchases can further enhance investment returns, ensuring stable gains amid market volatility.
See More
